CONTEXT: The association between aberrant (nuclear) beta-catenin expression and cyclin D1 accumulation has been demonstrated in diverse neoplasms. In synovial sarcoma (SS), aberrant beta-catenin expression has prognostic relevance, but the association with cyclin D1 has not been established. The SYT-SSX fusion protein, unique to SS, may independently increase cyclin D1. OBJECTIVE: To determine whether nuclear beta-catenin is associated with cyclin D1 overexpression in SS and whether primary and metastatic SS differ in the expression of these markers. DESIGN: We incorporated 82 tumors initially diagnosed as SS into a tissue array. Fluorescence in situ hybridization with custom probes was used to select t(X;18) positive tumors. Clinical data, tumor type and outcome were tabulated. The tumors were tested for the association between nuclear beta-catenin and cyclin D1 immunostaining. Primary and metastatic tumors were compared. RESULTS: Fifty-one tumors (41 primary and 10 metastatic) from 43 patients demonstrated t(X;18). Cyclin D1 staining was identified in 21 (59%) primary and 8 (80%) metastatic tumors, respectively, and nuclear beta-catenin in 24 (41%) primary and 7 (70%) metastatic tumors, respectively. No significant difference was noted between primary and metastatic tumors with respect to the above markers. The presence of nuclear beta-catenin showed a significant association with cyclin D1 expression (P < .001). A small number of cyclin D1 cases were negative for nuclear beta-catenin but positive for phosphorylated Akt. CONCLUSIONS: Increased cyclin D1 in SS may be driven by abnormally expressed beta-catenin, similar to other neoplasms. The pattern of expression of these markers is established early during tumorigenesis.
CONTEXT: The association between aberrant (nuclear) beta-catenin expression and cyclin D1 accumulation has been demonstrated in diverse neoplasms. In synovial sarcoma (SS), aberrant beta-catenin expression has prognostic relevance, but the association with cyclin D1 has not been established. The SYT-SSX fusion protein, unique to SS, may independently increase cyclin D1. OBJECTIVE: To determine whether nuclear beta-catenin is associated with cyclin D1 overexpression in SS and whether primary and metastatic SS differ in the expression of these markers. DESIGN: We incorporated 82 tumors initially diagnosed as SS into a tissue array. Fluorescence in situ hybridization with custom probes was used to select t(X;18) positive tumors. Clinical data, tumor type and outcome were tabulated. The tumors were tested for the association between nuclear beta-catenin and cyclin D1 immunostaining. Primary and metastatic tumors were compared. RESULTS: Fifty-one tumors (41 primary and 10 metastatic) from 43 patients demonstrated t(X;18). Cyclin D1 staining was identified in 21 (59%) primary and 8 (80%) metastatic tumors, respectively, and nuclear beta-catenin in 24 (41%) primary and 7 (70%) metastatic tumors, respectively. No significant difference was noted between primary and metastatic tumors with respect to the above markers. The presence of nuclear beta-catenin showed a significant association with cyclin D1 expression (P < .001). A small number of cyclin D1 cases were negative for nuclear beta-catenin but positive for phosphorylated Akt. CONCLUSIONS: Increased cyclin D1 in SS may be driven by abnormally expressed beta-catenin, similar to other neoplasms. The pattern of expression of these markers is established early during tumorigenesis.
Authors: Lisa M Rooper; Shih-Chiang Huang; Cristina R Antonescu; William H Westra; Justin A Bishop Journal: Hum Pathol Date: 2016-04-29 Impact factor: 3.466
Authors: Cheng-Han Lee; Rola H Ali; Marjan Rouzbahman; Adrian Marino-Enriquez; Meijun Zhu; Xiangqian Guo; Alayne L Brunner; Sarah Chiang; Samuel Leung; Nataliya Nelnyk; David G Huntsman; C Blake Gilks; Torsten O Nielsen; Paola Dal Cin; Matt van de Rijn; Esther Oliva; Jonathan A Fletcher; Marisa R Nucci Journal: Am J Surg Pathol Date: 2012-10 Impact factor: 6.394
Authors: Whitney Barham; Andrea L Frump; Taylor P Sherrill; Christina B Garcia; Kenyi Saito-Diaz; Michael N VanSaun; Barbara Fingleton; Linda Gleaves; Darren Orton; Mario R Capecchi; Timothy S Blackwell; Ethan Lee; Fiona Yull; Josiane E Eid Journal: Cancer Discov Date: 2013-08-06 Impact factor: 39.397
Authors: Fabio Bozzi; Andrea Ferrari; Tiziana Negri; Elena Conca; Da Riva Luca; Marco Losa; Paola Casieri; Marta Orsenigo; Andrea Lampis; Cristina Meazza; Michela Casanova; Marco A Pierotti; Elena Tamborini; Silvana Pilotti Journal: Transl Oncol Date: 2008-07 Impact factor: 4.243